CD200 expression marks leukemia stem cells in human AML

The leukemia stem cell (LSC) populations of acute myeloid leukemia (AML) exhibit phenotypic, genetic, and functional heterogeneity that contribute to therapy failure and relapse. Progress toward understanding the mechanistic basis for therapy resistance in LSCs has been hampered by difficulties in isolating cell fractions that enrich for the entire heterogeneous population of LSCs within individual AML samples. We previously reported that CD200 gene expression is upregulated in LSC-containing AML fractions. Here, we show that CD200 is present on a greater proportion of CD45(dim) blasts compared with more differentiated CD45(high) cells in AML patient samples. In 75% (49 of 65) of AML cases we examined, CD200 was expressed on >= 10% of CD45(dim) blasts; of these, CD200 identified LSCs within the blast population in 9 of 10 (90%) samples tested in xenotransplantation assays. CD200(+) LSCs could be isolated from CD200(+) normal HSCs with the use of additional markers. Notably, CD200 expression captured both CD34(-) and CD34(+) LSCs within individual AML samples. Analysis of highly purified CD200(+) LSC-containing fractions from NPM1-mutated AMLs, which are commonly CD34(-), exhibited an enrichment of primitive gene expression signatures compared with unfractionated cells. Overall, our findings support CD200 as a novel LSC marker that is able to capture the entire LSC compartment from AML patient samples, including those with NPM1 mutation.